Alternatively, therapy with anti-interleukin-5 monoclonal antibodies (mepolizumab, benralizumab) [29, 30, 31] or rituximab (monoclonal antibodies against CD20-positive B lymphocytes), which should preferably be carried out by vasculitis centers experienced in the treatment of EGPA [28]. The gene discussed is IL5; the disease is vasculitis.